Home / Glimipine-MV2
Image

Glimipine-MV2

Glimipine-MV2 is a triple-action therapy for type 2 diabetes, combining key ingredients to regulate blood sugar levels effectively. It improves insulin sensitivity, reduces glucose production, and slows carbohydrate absorption, ensuring consistent glycemic control for better diabetes management.

₹ 130

Test Specifications Results
Description White & orange colour elongated shape bilayered one side scored uncoated bilayered tablet. White & orange colour elongated shape bilayered one side scored uncoated bilayered tablet.
Identification By UV A 0.001 per cent w/v solution of metformin hydrochloride WS and test solution, as obtained in the assay, shows absorption maxima at 232 nm. Complies
Identification By HPLC In the assay of glimepiride the principal peak in the chromatogram obtained with the test solution correspondsto the principal peak in the chromatogram obtained with the reference solution. Complies
Average wt. of tablet 880 mg ± 5% (836.0 mg to 924.0 mg) 884.5 mg
Uniformity of wt. Average weight. ± 5% Max +2.88% Min -1.41%
Dissolution of Glimepiride NLT 75% of the stated amount Min - 95.86% to Max - 105.42%
Dissolution of Metformin HCL:(Sustained Release)
I- For 1st hour
2- For 3rd hour
3- For 10th hour
1- Between (25% to 50%)
2- Between (45% to 75%)
3- (NLT 80% of the stated amount)
Min - 34.7% to Max - 36.0%
Min - 67.0% to Max - 70.0%
Min - 89.1% to Max - 91.4%
Friability NMT 1.0% 0.15%
Uniformity of Content (Glimepiride) Between 85.0% 115.0% Complies
ASSAY:- (Each uncoated bilayered tablet contains)
Glimepiride IP 2mg
1.8 mg to 2.2 mg & 90% to 110% 2.0259 mg & 101.30%
ASSAY:- (Each uncoated bilayered tablet contains)
Metformin Hydrochloride(As Sustained Release) IP 500mg
450 0 mg to 550.0 mg & 90% to 110% 490.54 mg & 98.11%
ASSAY:- (Each uncoated bilayered tablet contains)
Voglibose IP 0.2mg
0.18 mg to 0.22 mg & 90% to 110% 0.1982 mg & 99.10%